Princess Margaret Cancer Centre
Princess Margaret Cancer Centre
Toronto, Ontario, Canada9 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors | Solid Tumor | Recruiting | Phase 1 | 2026-09-23 | NCT06619587 | |
| A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, endocrine system disorder, epithelial neoplasm, glioma, lung disorder, lung neoplasm, malignant endocrine neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, neuroepithelial neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, thyroid gland disorder, thyroid tumor | Active, not recruiting | Phase 1 | 2026-09-01 | NCT05355701 | |
| A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-08-20 | NCT06678659 | |
| TLN-372 in Advanced KRAS Mutant Solid Tumors | KRAS Mutant Solid Tumors | Recruiting | Phase 1 | 2026-07-28 | NCT07204340 | |
| Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, breast disorder, breast neoplasm, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, pancreas disorder, pancreatic neoplasm, prostate cancer, prostate disorder, skin disorder | Recruiting | Phase 1 | 2026-06-08 | NCT04890613 | |
| HN-QUEST: A Study of Head and Neck Imaging Biomarkers | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Recruiting | Not applicable | 2026-03-05 | NCT05919290 | |
| SUNSET: SBRT for Ultra-central NSCLC- a Safety and Efficacy Trial | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 1 | 2025-09-18 | NCT03306680 | |
| Multiple Myeloma Molecular Monitoring Study | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Not stated | 2025-06-29 | NCT03421132 | |
| PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2025-03-13 | NCT04557501 |